417 related articles for article (PubMed ID: 16603280)
1. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
Abdalrhman I; Gurt I; Katz E
Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
[TBL] [Abstract][Full Text] [Related]
2. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
4. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
5. [Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA].
Mahnel H; Mayr A
Berl Munch Tierarztl Wochenschr; 1994 Aug; 107(8):253-6. PubMed ID: 7945180
[TBL] [Abstract][Full Text] [Related]
6. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
7. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
8. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
[TBL] [Abstract][Full Text] [Related]
9. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.
Meseda CA; Weir JP
Future Microbiol; 2010 Sep; 5(9):1367-82. PubMed ID: 20860482
[TBL] [Abstract][Full Text] [Related]
10. Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.
He Y; Meseda CA; Vassell RA; Merchlinsky M; Weir JP; Weiss CD
Vaccine; 2010 Jan; 28(3):699-706. PubMed ID: 19887133
[TBL] [Abstract][Full Text] [Related]
11. Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants.
Hartnack S; Essbauer S; Truyen U
Zoonoses Public Health; 2008; 55(2):99-105. PubMed ID: 18234028
[TBL] [Abstract][Full Text] [Related]
12. Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response.
Lustig S; Maik-Rachline G; Paran N; Melamed S; Israely T; Erez N; Orr N; Reuveny S; Ordentlich A; Laub O; Shafferman A; Velan B
Vaccine; 2009 Mar; 27(11):1691-9. PubMed ID: 19195492
[TBL] [Abstract][Full Text] [Related]
13. [Development of a numerically additive combined vaccine against tetanus and smallpox].
Mayr A; Baljer G; Wagner C; Sailer J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr; 259(2):206-18. PubMed ID: 2990123
[TBL] [Abstract][Full Text] [Related]
14. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
Drexler I; Staib C; Kastenmuller W; Stevanović S; Schmidt B; Lemonnier FA; Rammensee HG; Busch DH; Bernhard H; Erfle V; Sutter G
Proc Natl Acad Sci U S A; 2003 Jan; 100(1):217-22. PubMed ID: 12518065
[TBL] [Abstract][Full Text] [Related]
15. Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara.
Staib C; Suezer Y; Kisling S; Kalinke U; Sutter G
J Gen Virol; 2006 Oct; 87(Pt 10):2917-2921. PubMed ID: 16963750
[TBL] [Abstract][Full Text] [Related]
16. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R.
Gurt I; Abdalrhman I; Katz E
Antiviral Res; 2006 Mar; 69(3):158-64. PubMed ID: 16406098
[TBL] [Abstract][Full Text] [Related]
17. The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments
de Freitas LFD; Oliveira RP; Miranda MCG; Rocha RP; Barbosa-Stancioli EF; Faria AMC; da Fonseca FG
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567985
[TBL] [Abstract][Full Text] [Related]
18. Vaccination against pox diseases under immunosuppressive conditions.
Mayr A; Danner K
Dev Biol Stand; 1978; 41():225-34. PubMed ID: 223909
[TBL] [Abstract][Full Text] [Related]
19. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.
Empig C; Kenner JR; Perret-Gentil M; Youree BE; Bell E; Chen A; Gurwith M; Higgins K; Lock M; Rice AD; Schriewer J; Sinangil F; White E; Buller RM; Dermody TS; Isaacs SN; Moyer RW
Vaccine; 2006 Apr; 24(17):3686-94. PubMed ID: 16430997
[TBL] [Abstract][Full Text] [Related]
20. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model.
Rees DG; Gates AJ; Green M; Eastaugh L; Lukaszewski RA; Griffin KF; Krieg AM; Titball RW
Antiviral Res; 2005 Feb; 65(2):87-95. PubMed ID: 15708635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]